Skip to main navigation
  • About SIGA
  • Products
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Contact Audit Committee
    • Stock Information
    • Investor FAQs
    • Investor Contact
  • News
  • Careers
  • Contact

SIGA: Human BioArmor

Providing solutions for unmet needs in health security
  • About SIGA
  • Products
  • Investors
  • News
  • Careers
  • Contact

Investors
  • Press Releases
  • Events & Presentations
  • Financial Information
    • SEC Filings
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
    • Contact Audit Committee
  • Stock Information
  • Investor FAQs
  • Investor Contact

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

  • Read more about SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

  • Read more about SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

SIGA Changes its 2020 Annual Meeting of Stockholders to Virtual Format

  • Read more about SIGA Changes its 2020 Annual Meeting of Stockholders to Virtual Format

SIGA Technologies Announces First International Delivery of Oral TPOXX®

  • Read more about SIGA Technologies Announces First International Delivery of Oral TPOXX®

Planning for Future Pandemics Including Smallpox Outbreaks: Interview with Dr. Phil Gomez, CEO, SIGA Technologies

  • Read more about Planning for Future Pandemics Including Smallpox Outbreaks: Interview with Dr. Phil Gomez, CEO, SIGA Technologies

SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020

  • Read more about SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020

SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results

  • Read more about SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results

SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence

  • Read more about SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence

SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019

  • Read more about SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019

SIGA Announces Collaboration with Turnstone Biologics

  • Read more about SIGA Announces Collaboration with Turnstone Biologics

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Shareholder Tools

Print
Email Alerts
RSS News Feeds
Contact IR

SIGA: Human BioArmor

  • Corporate Headquarters
    31 East 62nd Street
    New York, NY 10065
    (212) 672-9100

  • SIGA Development Operations
    4575 SW Research Way, Suite 110
    Corvallis, OR 97333
    (541) 753-2000

  • Privacy Notice

© SIGA Technologies, All Rights Reserved